Integrated workflow for pharmaceutical nitrosamine control from portfolio prioritization to formation risk, process purge, safety limit and lifecycle control.
Effective nitrosamine control requires coordination across regulatory, process chemistry, analytical development and toxicology. A fragmented assessment can miss important dependencies between formation, exposure and control.
Prioritize the portfolio
Products and APIs can be screened to focus resources on scenarios with greater theoretical risk.
Assess formation
Review susceptible amines, nitrosating conditions, degradation, excipients and manufacturing/storage factors.
Evaluate process control
Where applicable, assess purge or other process mechanisms that prevent the impurity reaching the final API/product.
Set the safety limit
Use the current agency value, compound-specific evidence, justified read-across or CPCA as applicable.
Verify and maintain control
Confirm analytically where required and reassess when process, supplier, formulation or regulatory information changes.
Frequently asked questions
Should acceptable intake be calculated before formation risk?
The activities interact, but formation risk determines which nitrosamines require attention and the safety limit defines the control target.
Can one software replace the multidisciplinary workflow?
No.
Do agency limits change?
Yes, which is why current EMA/FDA tables should be checked.
Is lifecycle review needed?
Yes.
